Aclarion, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $7.3M
- Price
- $2.95
- % Change (Daily % change from the live per-ticker quote feed.)
- -5.02%
- Volume
- 31.1K
Quote data as of 5:20 AM ET
About
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.
Quick stats
Shares outstanding2.5M
Computed float2.4M
Float sourceUnknown
Cash runway (months)Unknown
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryMedical - Healthcare Information Services
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001635077
Websitehttps://www.aclarion.com
AI Summary
AI-generated1mo agostandardbullishpartnershipAclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform
Aclarion has launched a Market Access Program in partnership with PRIA Healthcare to advance reimbursement and commercial adoption of its AI-powered Nociscan platform for chronic low back pain.
The collaboration leverages PRIA’s expertise in payer engagement, prior authorization, and appeals management to streamline the reimbursement process for U.S. physicians and health systems.
Nociscan has already secured payer approval from three of the top four private insurance companies in the UK, providing a validated foundation for Aclarion’s U.S. expansion strategy.